Metastatic breast cancer, version 1.2012: Featured updates to the NCCN guidelines

Robert W. Carlson; D. Craig Allred; Benjamin O. Anderson; Harold J. Burstein; Stephen B. Edge; William B. Farrar; Andres Forero; Sharon Hermes Giordano; Lori J. Goldstein; William J. Gradishar; Daniel F. Hayes; Clifford A. Hudis; Steven Jay Isakoff; Britt Marie E. Ljung; David A. Mankoff; P. Kelly Marcom; Ingrid A. Mayer; Beryl McCormick; Lori J. Pierce; Elizabeth C. Reed; Mary Lou Smith; Hatem Soliman; George Somlo; Richard L. Theriault; John H. Ward; Antonio C. Wolff; Richard Zellars; Rashmi Kumar; Dorothy A. Shead

doi:10.6004/jnccn.2012.0086

Metastatic breast cancer, version 1.2012: Featured updates to the NCCN guidelines

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, Stephen B. Edge, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Steven Jay Isakoff, Britt Marie E. Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. ReedMary Lou Smith, Hatem Soliman, George Somlo, Richard L. Theriault, John H. Ward, Antonio C. Wolff, Richard Zellars, Rashmi Kumar, Dorothy A. Shead

School of Medicine

Research output: Contribution to journal › Review article › peer-review

75 Scopus citations

Abstract

These NCCN Guidelines Insights highlight the important updates/changes specific to the management of metastatic breast cancer in the 2012 version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer. These changes/updates include the issue of retesting of biomarkers (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2) on recurrent disease, new information regarding first-line combination endocrine therapy for metastatic disease, a new section on monitoring of patients with metastatic disease, and new information on endocrine therapy combined with an mTOR inhibitor as a subsequent therapeutic option.

Original language	English (US)
Pages (from-to)	821-829
Number of pages	9
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	10
Issue number	7
DOIs	https://doi.org/10.6004/jnccn.2012.0086
State	Published - Jul 1 2012

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2012.0086

Cite this

Carlson, R. W., Allred, D. C., Anderson, B. O., Burstein, H. J., Edge, S. B., Farrar, W. B., Forero, A., Giordano, S. H., Goldstein, L. J., Gradishar, W. J., Hayes, D. F., Hudis, C. A., Isakoff, S. J., Ljung, B. M. E., Mankoff, D. A., Marcom, P. K., Mayer, I. A., McCormick, B., Pierce, L. J., ... Shead, D. A. (2012). Metastatic breast cancer, version 1.2012: Featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 10(7), 821-829. https://doi.org/10.6004/jnccn.2012.0086

Carlson, RW, Allred, DC, Anderson, BO, Burstein, HJ, Edge, SB, Farrar, WB, Forero, A, Giordano, SH, Goldstein, LJ, Gradishar, WJ, Hayes, DF, Hudis, CA, Isakoff, SJ, Ljung, BME, Mankoff, DA, Marcom, PK, Mayer, IA, McCormick, B, Pierce, LJ, Reed, EC, Smith, ML, Soliman, H, Somlo, G, Theriault, RL, Ward, JH, Wolff, AC, Zellars, R, Kumar, R & Shead, DA 2012, 'Metastatic breast cancer, version 1.2012: Featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 10, no. 7, pp. 821-829. https://doi.org/10.6004/jnccn.2012.0086

@article{dd95d701a78c4f0d98bf7c187b87ffb7,

title = "Metastatic breast cancer, version 1.2012: Featured updates to the NCCN guidelines",

abstract = "These NCCN Guidelines Insights highlight the important updates/changes specific to the management of metastatic breast cancer in the 2012 version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer. These changes/updates include the issue of retesting of biomarkers (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2) on recurrent disease, new information regarding first-line combination endocrine therapy for metastatic disease, a new section on monitoring of patients with metastatic disease, and new information on endocrine therapy combined with an mTOR inhibitor as a subsequent therapeutic option.",

author = "Carlson, {Robert W.} and Allred, {D. Craig} and Anderson, {Benjamin O.} and Burstein, {Harold J.} and Edge, {Stephen B.} and Farrar, {William B.} and Andres Forero and Giordano, {Sharon Hermes} and Goldstein, {Lori J.} and Gradishar, {William J.} and Hayes, {Daniel F.} and Hudis, {Clifford A.} and Isakoff, {Steven Jay} and Ljung, {Britt Marie E.} and Mankoff, {David A.} and Marcom, {P. Kelly} and Mayer, {Ingrid A.} and Beryl McCormick and Pierce, {Lori J.} and Reed, {Elizabeth C.} and Smith, {Mary Lou} and Hatem Soliman and George Somlo and Theriault, {Richard L.} and Ward, {John H.} and Wolff, {Antonio C.} and Richard Zellars and Rashmi Kumar and Shead, {Dorothy A.}",

year = "2012",

month = jul,

day = "1",

doi = "10.6004/jnccn.2012.0086",

language = "English (US)",

volume = "10",

pages = "821--829",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "7",

}

TY - JOUR

T1 - Metastatic breast cancer, version 1.2012

T2 - Featured updates to the NCCN guidelines

AU - Carlson, Robert W.

AU - Allred, D. Craig

AU - Anderson, Benjamin O.

AU - Burstein, Harold J.

AU - Edge, Stephen B.

AU - Farrar, William B.

AU - Forero, Andres

AU - Giordano, Sharon Hermes

AU - Goldstein, Lori J.

AU - Gradishar, William J.

AU - Hayes, Daniel F.

AU - Hudis, Clifford A.

AU - Isakoff, Steven Jay

AU - Ljung, Britt Marie E.

AU - Mankoff, David A.

AU - Marcom, P. Kelly

AU - Mayer, Ingrid A.

AU - McCormick, Beryl

AU - Pierce, Lori J.

AU - Reed, Elizabeth C.

AU - Smith, Mary Lou

AU - Soliman, Hatem

AU - Somlo, George

AU - Theriault, Richard L.

AU - Ward, John H.

AU - Wolff, Antonio C.

AU - Zellars, Richard

AU - Kumar, Rashmi

AU - Shead, Dorothy A.

PY - 2012/7/1

Y1 - 2012/7/1

N2 - These NCCN Guidelines Insights highlight the important updates/changes specific to the management of metastatic breast cancer in the 2012 version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer. These changes/updates include the issue of retesting of biomarkers (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2) on recurrent disease, new information regarding first-line combination endocrine therapy for metastatic disease, a new section on monitoring of patients with metastatic disease, and new information on endocrine therapy combined with an mTOR inhibitor as a subsequent therapeutic option.

AB - These NCCN Guidelines Insights highlight the important updates/changes specific to the management of metastatic breast cancer in the 2012 version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer. These changes/updates include the issue of retesting of biomarkers (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2) on recurrent disease, new information regarding first-line combination endocrine therapy for metastatic disease, a new section on monitoring of patients with metastatic disease, and new information on endocrine therapy combined with an mTOR inhibitor as a subsequent therapeutic option.

UR - http://www.scopus.com/inward/record.url?scp=84865341798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865341798&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2012.0086

DO - 10.6004/jnccn.2012.0086

M3 - Review article

C2 - 22773798

AN - SCOPUS:84865341798

SN - 1540-1405

VL - 10

SP - 821

EP - 829

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 7

ER -

Metastatic breast cancer, version 1.2012: Featured updates to the NCCN guidelines

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this